Document is current
Any future updates will be listed below
-
Authors
Satti, Iman
Wittenberg, Rachel E. https://orcid.org/0000-0002-0823-5635
Li, Shuailin
Harris, Stephanie A.
Tanner, Rachel
Cizmeci, Deniz https://orcid.org/0000-0003-3231-7726
Jacobs, Ashley
Williams, Nicola https://orcid.org/0000-0002-7476-9715
Mulenga, Humphrey
Fletcher, Helen A. https://orcid.org/0000-0002-0435-1006
Scriba, Thomas J. https://orcid.org/0000-0002-0641-1359
Tameris, Michele https://orcid.org/0000-0002-7983-7203
Hatherill, Mark https://orcid.org/0000-0003-3491-1809
McShane, Helen https://orcid.org/0000-0002-2126-5142
- License Information
-
More Information
Article History
Received: 7 May 2022
Accepted: 12 October 2022
First Online: 3 November 2022
Competing interests
: H.M. was previously a shareholder in the Oxford-Emergent Tuberculosis Consortium (OETC), a joint venture established for the development of MVA85A (OETC no longer exists). The remaining authors declare no competing interests.
